Besun Pharmaceutical settled in Dongyang to tackle key angiogenesis projects

The signing ceremony of the class 1 innovative drug project for angiogenesis, which was developed by Rebiosun Pharma, was held in the conference room of Dongyang Administrative Center a few days ago.

Lou Langjian, Deputy Secretary of Dongyang Municipal Party Committee and Mayor, attended the signing ceremony and delivered a speech. Chen Hong, Executive Deputy Mayor of Dongyang City, presided over the signing ceremony. Relevant leaders and representatives of investors participated.

Dr. Li Ming, the representative of the project party, introduced the research and development background of the project, the characteristics, advantages and related progress plans of new drugs to the leaders and guests.

Shao Xiangrong, the representative of the investor and vice president of Zhejiang Tsinghua Yangtze River Delta Research Institute, delivered a speech, expressing his confidence in the research and development and application prospects of the project.

On behalf of the project investor, Dr. Li Ming signed an investment agreement with Wang Saifeng, Secretary of the Party Working Committee of Jiangbei Street.

It is understood that the R&D and Industrialization Project of Innovative Drugs for Ischemic Stroke strives to provide curative treatment of pathological changes in ischemic stroke through regenerative medicine, and apply it to the acute phase, recovery phase, and sequelae of ischemic stroke. period, as well as primary and secondary prevention, so as to achieve breakthroughs in the research and development of new drugs for the treatment of major human diseases. The project plans to enter the application channel of innovative drugs in the near future, and at the same time, through legal channels, the common people can enjoy the significant effects of the drug as soon as possible to solve their pain; Patients are provided with green drugs with obvious therapeutic effects and no toxic side effects.

Biomedical industry is one of Dongyang's leading industries. In recent years, Dongyang City has attached great importance to the development of the biopharmaceutical industry, taking the lead in introducing the province's first county-level high-value pharmaceutical incentive policy, actively improving the supporting construction, creating a workstation for academicians and experts of pharmaceutical companies, and a provincial-level enterprise research institute to increase the attraction of the project. As a high-tech innovative enterprise specializing in the R&D, production and sales of innovative natural plant drugs, the successful settlement of Besun Pharmaceuticals in Dongyang is inseparable from the local government's emphasis on and support for related industries. The company will take this as the driving force, adhere to the mission of conquering major human diseases, tackle the research and development and industrialization projects of innovative drugs for ischemic stroke, and contribute to the cause of human health through innovative products, co-building platforms, and giving back to the society. strength.